The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Natco Pharma intends to defend the matter accordingly
Cipla completes transfer of Generics Business Undertaking
The observations do not pose any risk to site's compliance standards or its business continuity
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
InvaGen has received 5 inspectional observations in Form 483
The company has entered into a three-year Deferred Prosecution Agreement
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)